Federal Drug Reform Bill Would Weigh Prohibition Harms in Marijuana Scheduling Decisions

Federal Drug Reform Bill Would Weigh Prohibition Harms in Marijuana Scheduling Decisions

The Bill and Its Sponsor

Rep. Steve Cohen (D-Tenn.) has introduced the Public Health and Research Reforms in Controlled Substances Act of 2026. The bill would move core scheduling and research authority from the Department of Justice to the Department of Health and Human Services.

It would also remove marijuana from the list of controlled substances. The FDA would retain authority over cannabis products.

Since the Controlled Substances Act of 1970, the DEA has held primary authority over drug scheduling decisions. Federal health agencies supply scientific input, but the ultimate decision has rested with law enforcement.

The bill’s most consequential change concerns how scheduling decisions are made, not merely which agency makes them. It would require the government to weigh the costs of prohibiting a drug, not just the risks the drug itself might pose.

Current law does not ask the government to weigh a drug’s potential harm against the harms of prohibiting it. Cohen’s bill makes that comparison mandatory.

How Scheduling Would Change

Officials would have to consider as a factor “what threat to public health, if any, from scheduling the drug or other substance, including replacement by alternative drugs or substances.”

They would also consider whether a drug is currently being used to reduce people’s dependence on other harmful substances.

The bill replaces the current five schedules with a dual approach. A drug would receive a Roman numeral (I through IV) reflecting its risk of misuse, potential for dependence, and threat to public health, plus a letter (A through E) reflecting its therapeutic value.

A drug could therefore be classified as high-risk while still being recognized as substantially beneficial in a medical context. Fentanyl is cited as an example of a drug that carries significant risks but remains indispensable in surgery.

A new 15-to-25-member expert committee appointed by HHS would conduct a transparent “multicriteria decision analysis,” scoring substances against 15 factors. Its analysis would be published and available to the public.

Enforcement and Marijuana Provisions

The attorney general would supply a law enforcement evaluation on the single factor of illicit manufacturing and trafficking. The attorney general and the Office of National Drug Control Policy could request and initiate scheduling action, but HHS would make the ultimate determination.

The bill would replace the undefined “imminent hazard to the public safety” emergency scheduling standard with a defined “imminent significant threat to public health” standard. Initiation of emergency scheduling would shift from the attorney general to the ONDCP director.

The bill eliminates quantity-based mandatory minimum sentences for trafficking while keeping maximum limits, including up to life in prison where death or serious bodily injury occurs.

It preserves enhanced penalties for repeat offenders and serious drug felonies. It also creates a resentencing pathway and requires the Bureau of Prisons to identify eligible prisoners and file motions on their behalf.

Marijuana and THC would come off the schedules entirely, though the bill allows continued marijuana testing of federal employees. The bill does not end the federal government’s punitive approach to drug policy.

Related Stories

Friday
administrator
Friday is a San Diego based writer covering cannabis news, culture, and business. Known for sharp analysis and clean reporting, Friday helps readers navigate the industry without the fluff. Every article is built on research, real sources, and a deep commitment to the cannabis community.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *